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Objectives We aimed to perform a meta-analysis of clinical trials on intracoronary cell therapy after acute myocardial
infarction (AMI).
Background Intracoronary cell therapy continues to be evaluated in the setting of AMI with variable impact on left ventricular
ejection fraction (LVEF).
Methods We searched the CENTRAL, mRCT, and PubMed databases for controlled trials reporting on intracoronary cell
therapy performed in patients with a recent AMI (14 days), revascularized percutaneously, with follow-up of
3 months. The primary end point was change in LVEF, and secondary end points were changes in infarct size,
cardiac dimensions, and dichotomous clinical outcomes.
Results Ten studies were retrieved (698 patients, median follow-up 6 months), and pooling was performed with random
effect. Subjects that received intracoronary cell therapy had a significant improvement in LVEF (3.0% increase
[95% confidence interval (CI) 1.9 to 4.1]; p  0.001), as well as a reduction in infarct size (5.6% [95% CI 8.7
to 2.5]; p  0.001) and end-systolic volume (7.4 ml [95% CI 12.2 to 2.7]; p  0.002), and a trend to-
ward reduced end-diastolic volume (4.6 ml [95% CI 10.4 to 1.1]; p  0.11). Intracoronary cell therapy was
also associated with a nominally significant reduction in recurrent AMI (p  0.04) and with trends toward re-
duced death, rehospitalization for heart failure, and repeat revascularization. Meta-regression suggested the ex-
istence of a dose-response association between injected cell volume and LVEF change (p  0.066).
Conclusions Intracoronary cell therapy following percutaneous coronary intervention for AMI appears to provide statistically
and clinically relevant benefits on cardiac function and remodeling. These data confirm the beneficial impact of
this novel therapy and support further multicenter randomized trials targeted to address the impact of intracoro-
nary cell therapy on overall and event-free long-term survival. (J Am Coll Cardiol 2007;50:1761–7) © 2007 by
the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.07.041t
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Whe treatment of acute myocardial infarction (AMI), espe-
ially ST-segment elevation, centers on early revasculariza-
ion of the infarct-related artery and optimal medical
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ccepted July 17, 2007.herapy. Although multiple studies have more recently
nvestigated the potential role of intracoronary cell therapy
or AMI (1–16), it remains unclear whether intracoronary
ell therapy improves left ventricular (LV) function, LV
imensions, infarct size, and other clinical outcomes. Our
oal was to systematically review controlled clinical trials
ppraising the impact of intracoronary cell therapy on
ost-infarction LV function.
ethods
e searched (September 2006) the CENTRAL, mRCT,
nd PubMed databases, as well as years 2000 to 2006
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American Heart Association,
European Society of Cardiology,
and Transcatheter Cardiovascu-
lar Therapeutics conference pro-
ceedings without language restric-
tion, using as keywords: “cells
AND (intracoronary OR trans-
coronary).” Initially selected cita-
tions were screened at the title/
abstract level and, if potentially
relevant, retrieved and assessed as
complete manuscripts for compli-
ance with these inclusion criteria:
1) prospective comparison of in-
tracoronary cell therapy versus
control after AMI in which the
infarct-related artery was percuta-
neously revascularized; 2) intention-
to-treat analysis; and 3) follow-up
of 3 months. Exclusion criteria
were: 1) irretrievable or unclear
ata; 2) treatment of old MI (14 days), chronic ischemia,
r heart failure; 3) lack of control group; 4) duplicate
eports; and 5) ongoing or unpublished studies.
Several study features were extracted, including design,
utcome definitions, imaging modalities, patient baseline
haracteristics, and procedural data. Specifically, the pri-
ary end point was the change in left ventricular ejection
raction (LVEF) from baseline to follow-up. Secondary
fficacy end points were changes in left ventricular end-
ystolic volume (LVESV), left ventricular end-diastolic
olume (LVEDV), and infarct size. In case a remodeling
arameter was reported by more than 1 imaging technique,
he 1 with the smaller standard error was chosen for
nalysis. Secondary safety end points were the incidence of
ichotomous clinical events (i.e., death, recurrent AMI,
arget vessel revascularization [TVR], and rehospitalization
or heart failure) evaluated at the longest available follow-
p. All of the outcomes analyzed were used as defined in
ndividual trials. In case of missing or unclear data for the
rimary or secondary end points, at least 2 separate attempts
ere made to clarify the data by contacting the primary
uthors at least 3 weeks apart. The internal validity of
ncluded trials was appraised separately, addressing the risk
f selection, performance, adjudication, and attrition bias.
tudy search, selection, abstraction, and appraisal were all
erformed by 2 independent reviewers, with divergences
esolved with consensus.
Dichotomous variables are reported as proportions and
ercentages, continuous variables as mean  standard de-
iation or median (interquartile range [IQR]). Binary out-
omes from individual studies were combined with the Peto
xed-effect model, unless inconsistency (I2)50%, in which
ase a random-effect model was used to compute odds ratios
Abbreviations
and Acronyms
AMI  acute myocardial
infarction
BMC  bone marrow cell
CI  confidence interval
G-CSF  granulocyte
colony-stimulating factor
LV  left ventricular
LVEDV  left ventricular
end-diastolic volume
LVEF  left ventricular
ejection fraction
LVESV  left ventricular
end-systolic volume
OR  odds ratio
PMC  peripheral
mononuclear cell
TVR  target vessel
revascularizationORs) with 95% confidence intervals (CIs). Continuous wariables were pooled with a random-effect generic-inverse-
ariance method, providing summary point estimates (95%
I). Chi-square tests and I2 were computed to explore
tatistical heterogeneity and inconsistency, respectively.
mall study bias was explored with funnel plots and Egger
est. Finally, meta-regression and sensitivity analyses (in-
luding exclusion of 1 study at a time) were conducted to
xplore heterogeneity. Computations were performed using
evMan 4.2 (The Cochrane Collaboration, Copenhagen,
enmark) and SPSS 11.0 (SPSS, Chicago, Illinois), with
tatistical significance for hypothesis testing set at the 0.05,
-tailed level.
esults
rom the initial 666 hits, 601 citations were initially
xcluded at the title/abstract level (Fig. 1). Among the
rticles retrieved in complete form, 5 were excluded for lack
f a control group (3,14), 16 for investigating a different end
oint, 15 with intracoronary cell therapy for chronic coro-
ary disease or heart failure, 2 because they were ongoing or
npublished, 14 because they were related to surgical
elivery or other therapies involving cell therapy, and 1
ecause the average time from symptom onset to cell
njection was 14 days (6). Eventually, 11 articles covering
0 controlled trials were included in the analysis
2,4,5,7,8,10–13,15,16). The 10 included trials allocated
98 patients to intracoronary cell therapy or standard
edical therapy (Tables 1 to 4), with a mean follow-up of
months (range 3 to 18 months).
Meta-analytic pooling for the primary end point showed
hat intracoronary cell therapy was significantly superior to
tandard medical therapy in terms of LVEF improvement,
Figure 1 Review Process
This scheme provides a summary of the systematic reviewing process.ith a clinically and statistically significant difference of
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October 30, 2007:1761–7 Cell Therapy After AMI.0% (95% CI 1.9% to 4.1%; p  0.00001; I2  73.2%).
ntracoronary cell therapy was similarly found to have
enefit concerning LVESV (average difference 7.4 ml
95% CI 12.2 to 2.7]; p  0.002; I2  95.8%) and
nfarct size (average difference  5.6% [95% CI 8.7 to
2.5]; p  0.0004; I2  92.6%). There was a trend for
mprovement in LVEDV (average difference 4.6 ml [95%
I 10.4 to 1.1]; p  0.11; I2  95.2%) (Fig. 2).
Comparing dichotomous clinical end points (Table 4),
ntracoronary cell therapy proved to be notably safe, without
ny increase in the risk of TVR (OR 1.08 [95% CI 0.60 to
.96]; p 0.80; I2 25.3%). Conversely, intracoronary cell
herapy tended to be associated, albeit nonsignificantly, with
eductions in the risk of death or rehospitalization for heart
ailure. In addition, intracoronary cell therapy was associ-
ted with a nominally statistically significant decrease in
ecurrent AMI (p  0.04), but this finding should be
egarded as hypothesis-generating only, given the low num-
er of events in all but 1 of the studies (5).
A number of exploratory meta-regression analyses were
erformed to appraise the impact of the following moder-
tor or covariates on the changes in LVEF associated with
ntracoronary cell therapy. Specifically, at the overall analysis
e did not find statistically significant association between:
ain Features of Included Studies
Table 1 Main Features of Included Studies
Study Year Design
Patients Enrolled
(Patients at Follow-Up) C
Strauer et al. (10) 2002 Non-RCT 20 (20)
Bartunek et al. (11) 2005 Non-RCT 35 (35)
Jannsens et al. (8) 2006 RCT 67 (66)
BOOST (7) 2006 RCT 60 (60)
Zhan-Quan et al. (13) 2006 Non-RCT 70 (58)
MAGIC CELL-3-DES (12) 2006 RCT 56 (50)
TCT-STAMI (15) 2006 RCT 20 (20)
ASTAMI (2,4) 2006 RCT 100 (97)
REPAIR-AMI (5) 2006 RCT 204 (187)
Meluzin et al. (16) 2006 RCT 66 (66)
MC  bone marrow cells; EDV  end-diastolic volume; LV  left ventricular; LVEF  left ventricu
andomized controlled trial; SPECT  single-photon emission computed tomography; WMSI  wa
atients and Procedural Characteristics of Included Studies
Table 2 Patients and Procedural Characteristics of Included St
Study
Mean
Age
(yrs)
Men
(%)
Anterior
AMI
(%)
Hours t
PCI
Strauer et al. (10) 50 92.5 37.5 11.5
Bartunek et al. (11) 54 91 94 10
Jannsens et al. (8) 57 82 63 3.9
BOOST (7) 56 70 77 8.9
Zhan-Quan et al. (13) 60 80 60 24
MAGIC CELL-3-DES (12) 60 80 54 9.1
TCT-STAMI (15) 58 90 70 7.5
ASTAMI (2,4) 57 84 100 3.5
REPAIR-AMI (5) 56 82 78 7.2
Meluzin et al. (16) 55 92.4 85 7.7MI  acute myocardial infarction; DES  drug-eluting stent; ICT  intracoronary cell therapy; NP  nothe benefits of intracoronary cell therapy and follow-up
uration (p 0.73), year of publication (p 0.54), baseline
VEF in the experimental group (p  0.32), number of
njected cells (p  0.69), time to PCI (p  0.40), and time
etween symptom onset (p  0.72). However, we found a
rend toward a statistically significant association between
njected volume and LVEF (p  0.066), suggesting the
ossible presence of a dose-response relationship (Fig. 3).
No evidence of small-study bias was found either visually
t inspection of funnel plots or analytically at Egger test
p  0.57). Computations performed after selecting only
andomized trials or high-quality randomized trials
4,5,7,8,11) (Table 3) confirmed the statistically significant
mprovement of LVEF (respectively: 3.8% [95% CI 2.2 to
.5]; p  0.00001; I2  87.8%; and 2.8% [95% CI 1.3 to
.3]; p  0.001; I2  70.9%). Indeed, we found no major
ifferences in LVEF effect size between randomized and
onrandomized studies.
Similarly significant was the effect on LVEF when
electing only studies using a sham intracoronary infusion
or the control group (3.0% change [95% CI 0.8 to 5.2];
 0.008; I2  79.4%). Finally, sensitivity analysis
xcluding 1 study at a time confirmed in direction and
agnitude of statistical significance the results from the
e
Follow-Up
(Months) Primary End Point
Imaging Modality
for LVEF Assessment
3 LVEF LV angiography
4 Safety, LVEF LV angiography, SPECT
4 LVEF Cardiac MRI
18 LVEF, safety Cardiac MRI
6 LVEF, LV volumes, WMSI Echocardiography
6 LVEF Cardiac MRI
6 LVEF Echocardiography, SPECT
6 LVEF, EDV, infarct size SPECT, MRI, echo
12 LVEF LV angiography
3 Infarct zone systolic function SPECT
ction fraction; MRI  magnetic resonance imaging; PMC  peripheral mononuclear cells; RCT 
n score index.
DES
Use
(%)
Days to
ICT
Average Number
of Injected Cells
(106)
CD34
Cells
(106)
Injected
Volume
(ml)
0 8 46 NP 20
8.6 11.6 NP 15.4 15–20
NP 1 304 2.8 10
NP 4.8 2,460 9.5 26
NP 6 72.5 NP 57
100 4 1,500 7 NP
NP 0.5 38.7 1.8 16
5 6 68 0.7 NP
14.5 4.4 236 3.6 10
NP 7 55 0.55 21ell Typ
BMC
BMC
BMC
BMC
PMC
PMC
BMC
BMC
BMC
BMCudies
oprovided; PCI  percutaneous coronary intervention.
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Cell Therapy After AMI October 30, 2007:1761–7verall analysis (all p values 0.001). Analysis comparing
he effect of bone marrow cells (BMCs) versus peripheral
ononuclear cells (PMCs) could not be performed because
f inadequate power due to the low number of studies using
ntracoronary delivery of peripheral cells (12,13). However, the
mpact of intracoronary cell therapy on LVEF was investigated
or both BMCs and PMCs and demonstrated that intracoro-
ary cell therapy improves LVEF, regardless of whether
MCs (3.3% [95% CI 1.8 to 5.2]; p  0.001; I2  84.1%) or
MCs (5.3% [95% CI 4.1 to 6.7]; p  0.001; I2  0%) were
sed.
iscussion
he main finding of the present study is that intracoronary
ell therapy after AMI results in a modest yet significant
ncrease in LVEF compared with control. In addition, analysis
f secondary end points demonstrates that intracoronary cell
herapy significantly decreases LVESV and infarct size. This
eta-analysis included intracoronary cell therapy derived from
oth BMCs and PMCs. Although this may be argued as a
imitation of the study, intracoronary cell therapy after AMI
nternal Validity of Included Trials*
Table 3 Internal Validity of Included Trials*
Study Setting Allocation Concealment
Strauer et al. (10) Single-center None (nonrandom allocation)
Bartunek et al. (11) Single-center None (nonrandom allocation)
Jannsens et al. (8) Single-center Likely adequate
BOOST (7) Single-center Unclear
Zhan-Quan et al. (13) Single-center None (nonrandom allocation)
MAGIC-CELL-3-DES (12) Single-center Likely inadequate (open table of
randomized allocations)
TCT-STAMI (15) Single-center Likely adequate
ASTAMI (2,4) 2 centers Unclear
REPAIR-AMI (5) Multicenter Likely adequate
Meluzin et al. (16) Single-center Unclear
The internal validity of included trials was appraised by judging separately the risk for selection,
C) of bias or incomplete reporting leading to inability to ascertain the underlying risk of bias (D).
Clinical Events at the Longest Available Follow-as Reported by Included Studies nd Pooled Wi
Table 4 Clinical Events at the Longest Avaias Reported by Included Studies an
Study Death
Recurr
I
Strauer et al. (10) —
Bartunek et al. (11) 0/19 vs. 0/16
Jannsens et al. (8) 1/34 vs. 0/34 0/
BOOST (7) 0/30 vs. 1/30 1/
Zhan-Quan et al. (13) 0/35 vs. 0/23 0/
MAGIC-CELL-3-DES (12) 1/27 vs. 1/29 0/
TCT-STAMI (15) 0/10 vs. 0/10 0/
ASTAMI (2,4) 0/50 vs. 0/50
REPAIR-AMI (5) 2/101 vs. 6/103 0/1
Meluzin et al. (16) 0/44 vs. 0/22 0/
OR (95% CI) 0.52 (0.16–1.63) 0.22
p value 0.26*Comparing intracoronary cell therapy versus control event rates (n/N).
CI  confidence interval; OR  odds ratio.ppears to improve LVEF regardless of whether BMCs or
MCs are employed. It is important to recognize that the
utlying study by Chen et al. (6) was excluded, because
herapy was initiated 14 days after symptoms.
The question of whether a small increase in LVEF is of
linical significance is an important issue. However, it
hould be stressed that many of the interventions with an
stablished life-saving effect during or after AMI also
rovide only moderate yet clinically meaningful increases
n LVEF. Several hypotheses have been proposed about
ow intracoronary cell therapy improves myocardial function.
ecent well-conducted studies suggest that bone marrow-
erived cells do not transdifferentiate into cardiomyocytes but
dopt mature hematopoeitic characteristics (17,18). However,
dult peripheral blood CD34 cells can transdifferentiate into
ardiomyocytes, mature endothelial cells, and smooth muscle
ells in vivo (19). Another proposed mechanism is that cell
herapy may increase angiogenesis and improve blood sup-
ly to ischemic regions, potentially aiding in the revascular-
zation of hibernating myocardium (20) and inhibiting
ardiomyocyte apoptosis (21).
Sham
Infusion
Selection
Bias
Performance
Bias
Adjudication
Bias
Attrition
Bias
No C C C A
No C C C D
Yes A A B A
No B B A A
No C C C B
No B B A A
Yes A A C D
No B B D A
Yes A A A A
No A B D A
ance, attrition, and adjudication biases, expressed as low risk (A), moderate risk (B), or high risk
to Method*
Follow-Up
oled With Peto Method*
yocardial
ion
Target Vessel
Revascularization
Rehospitalization
for Heart Failure
— —
11/19 vs. 4/16 —
0/34 2/33 vs. 2/34 —
0/30 5/30 vs. 4/30 1/30 vs. 3/30
0/23 0/35 vs. 0/23 0/35 vs. 0/23
1/29 0/27 vs. 1/29 —
0/10 0/10 vs. 0/10 0/10 vs. 0/10
11/50 vs. 11/50 1/50 vs. 1/50
6/103 16/101 vs. 26/103 0/101 vs. 3/103
0/22 6/44 vs. 1/22 0/44 vs. 0/22
–0.90) 0.97 (0.62–1.52) 0.32 (0.09–1.21)
0.90 0.09Upth Pe
lable
d Po
ent M
nfarct
—
—
33 vs.
30 vs.
35 vs.
27 vs.
10 vs.
—
01 vs.
44 vs.
(0.05
0.04
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October 30, 2007:1761–7 Cell Therapy After AMIFigure 2 Impact of Intracoronary Cell Therapy on Left Ventricular Remodeling
Forest plots show the significantly beneficial impact of cell therapy after myocardial infarction on (A) left ventricular ejection fraction (EF), (B) end-systolic volume (ESV),
(C) end-diastolic volume (EDV), and (D) infarct size/functional defect at myocardial scintigraphy or late enhancement at magnetic resonance imaging. CI  confidence
interval; I2  inconsistency; SE  standard error.
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Cell Therapy After AMI October 30, 2007:1761–7Cells were harvested either by bone marrow biopsy or
y daily granulocyte colony-stimulating factor (G-CSF)
njections for 3 to 5 days followed by apheresis and
elivered via an over-the-wire balloon catheter. However,
ontroversy exists as to whether G-CSF injections alone
fter AMI improve LV function (22). Therefore, the
AGIC Cell-3-DES (Myocardial Infarction With G-CSF
nd Intra-Coronary Stem Cell Infusion-3-Drug Eluting
tents) trial (12) and the study by Li et al. (13) are
nherently different from other studies included in this
nalysis owing to the use of G-CSF. Additionally, Bartunek
t al. (11) primarily delivered CD133 cells. Cell isolation
rotocols before delivery have also been shown to have an
mpact on cell functional activity (23). Finally, Hofmann et
l. (24) demonstrated the impact of cell line on cellular
etention in the myocardium, with detection of only 1% to
% of unselected BMCs after intracoronary transfer,
hereas 14% to 39% of CD34-enriched labeled cells were
etected. Our incomplete understanding of the complex
xtra- and intracellular signaling that governs cell homing
nd differentiation is currently a major limitation of this
echnique. On the other hand, despite previous concerns
ver a potential increase in in-stent restenosis after cell
herapy (14,25), we found that TVR was not increased in
ell therapy recipients.
tudy limitations. Limitations of systematic reviews are
ell known. Drawbacks pertinent to the present study
nclude lack of raw and uniform data from included studies,
Figure 3 Metaregression Between Injected
Volume and Left Ventricular Remodeling
L’Abbé plot shows the overall trend toward a statistically significant association
between average volume injected in the culprit coronary artery and average
change in left ventricular ejection fraction (LVEF) across included studies
(squares), with the size of each square proportional to sample size. This trend
supports the presence of a dose-response relationship.nclusion of papers using intracoronary PMCs and BMCs,ariation in imaging techniques and revascularization strat-
gies, and large differences in time from AMI to cell
herapy, as well as pooling nonrandomized and randomized
rials. However, maintenance of significance when selecting
nly randomized trials lends support to the robustness of
ur overall analysis.
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